Compare Organon & Co. Common Stock (OGN) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Quantumscape Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Quantumscape Corp trades at $3.88 (market cap $2.55B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Quantumscape Corp for 37 Days on average.
| OGN | QS | |
|---|---|---|
Market Cap | $3.62B | $2.55B |
Volume | 2,892,999 | 12,145,789 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $18.44 |
52-Week Low | $5.70 | $3.93 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $11.04B | $1.76B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
QuantumScape (QS) trades at $3.93, down 7.96% today, reflecting ongoing investor skepticism about its path to commercialization. The company remains pre-revenue with significant losses (-$435.05M net income in 2025) and negative profitability metrics (ROE -39.08%). Technical indicators show a bearish trend with oversold RSI readings, while analyst consensus leans heavily toward Hold (72.73%) with a $10.35 price target suggesting potential upside if execution improves.
QS faces substantial execution risk with commercialization delayed until at least 2029 and intense competition in solid-state batteries. The stock offers high-risk speculative potential for investors betting on breakthrough technology adoption, but requires patience through years of cash burn and dependency on future manufacturing success with partners like Volkswagen.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
